Login / Signup

A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.

Dylan B NessDarcy B PoolerSteven AdesBrian J HighhouseBridget M LabrieAnne G HoenJiang GuiLionel D LewisMarc S Ernstoff
Published in: Cancer medicine (2023)
Alternating sunitinib and temsirolimus did not improve the PFS in patients with mRCC.
Keyphrases
  • metastatic renal cell carcinoma
  • phase ii study
  • open label
  • locally advanced
  • placebo controlled
  • randomized controlled trial
  • clinical trial
  • rectal cancer
  • squamous cell carcinoma
  • mesenchymal stem cells
  • bone marrow